<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03915262</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL19_0294</org_study_id>
    <nct_id>NCT03915262</nct_id>
  </id_info>
  <brief_title>Exocrine Pancreatic Insufficiency's Prevalence in Active Crohn's Disease</brief_title>
  <acronym>IPEC</acronym>
  <official_title>Exocrine Pancreatic Insufficiency's Prevalence in Active Crohn's Disease Treated by Biological Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess the prevalence of exocrine pancreatic insufficiency (EPI) in a
      population of patients with active Crohn's disease. Studies already describe a prevalence
      rate around 18-66%. In this multicentric prospective study, we plan to compare EPI's
      prevalence at week 0 and week 14 of an induction phase of a biological therapy. The
      biological therapy will be initiate for an active Crohn's disease. Secondary outcomes will
      be: malnutrition's prevalence, and Crohn's disease activity level.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2, 2019</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Exocrine pancreatic insufficiency's prevalence</measure>
    <time_frame>week 0</time_frame>
    <description>Exocrine pancreatic insufficiency will be defined as the association of : fecal elastase &lt;200 mcg/g and steatorrhea (&gt;7g of fecal fat per day) or an fat absorption rate &lt; 95%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Exocrine pancreatic insufficiency's prevalence</measure>
    <time_frame>week 14</time_frame>
    <description>Exocrine pancreatic insufficiency will be defined as the association of : fecal elastase &lt;200 mcg/g and steatorrhea (&gt;7g of fecal fat per day) or an fat absorption rate &lt; 95%</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Crohn Disease</condition>
  <arm_group>
    <arm_group_label>Crohn's Disease</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Search for exocrine pancreatic insufficiency at week 0 and 12</intervention_name>
    <description>We will collect 24 hours stool to search for steatorrhea, and to measure elastase and calprotectin.
We will collect a total of 8 additional blood tubes (25mL), during regular blood sampling for a patient under biological therapy for a Crohn's disease.
We will gather the total caloric and fat intake with a diet record.</description>
    <arm_group_label>Crohn's Disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with an active Crohn's Disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of 18 years or more

          -  Crohn's disease diagnosed for more than 3 months.

          -  Active Crohn's disease : CDAI score &gt; 150 + [CRP &gt; 5 mg/L or faecal calprotectin &gt;
             250mcg/g or endoscopic lesion or MRI lesion]

          -  Indication of a biological therapy (anti-TNFα, vedolizumab ou ustekinumab).

        Exclusion Criteria:

          -  Crohn's disease that doesn't fit the previous criteria

          -  Extended resection of small intestine (&gt;40cm)

          -  Chronic pancreatitis diagnosed before inclusion

          -  Contraindication to biological therapy (anti-TNFα, vedolizumab ou ustekinumab)

          -  Pancreatic enzyme replacement therapy

          -  Pregnant or breastfeeding woman

          -  Patient under the protection of a conservator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles BOSCHETTI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilles BOSCHETTI, MD</last_name>
    <phone>478860302</phone>
    <phone_ext>+33</phone_ext>
    <email>gilles.boschetti@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charlotte BERGOIN, MD</last_name>
    <phone>478863869</phone>
    <phone_ext>+33</phone_ext>
    <email>charlotte.bergoin@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service d'Hépato-Gastroentérologie, Centre Hospitalier Lyon-Sud, HCL</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles BOSCHETTI, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Charlotte BERGOIN, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Gilles BOSCHETTI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphane NANCEY, MD, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernard FLOURIE, MD, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charlotte BERGOIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>April 9, 2019</study_first_submitted>
  <study_first_submitted_qc>April 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2019</study_first_posted>
  <last_update_submitted>December 2, 2019</last_update_submitted>
  <last_update_submitted_qc>December 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

